Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-22-Speech-3-197"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20100922.20.3-197"2
lpv:hasSubsequent	lp_eu:2010-09-22-Speech-3-1982
lpv:speaker	lp:Aldo Patriciello2
lpv:spokenAs	member; CONT (2009-07-16--2012-01-18)3 member; ITRE (2009-07-16--2012-01-18)3 substitute; REGI (2009-07-16--2012-01-18)3 substitute; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia Parliamentary Cooperation Committees (2009-09-16--2014-06-30)3 unknown; Il Popolo della Libertà (2009-07-14--2013-12-05)3 member; Delegation for relations with Albania, Bosnia and Herzegovina, Serbia, Montenegro and Kosovo (2009-09-16--2014-06-30)3 member; EPP (2009-07-14--2014-06-30)3
lpv:translated text	"Medicinal products play a crucial role in the health of European citizens; nevertheless, they can have adverse effects which, according to the European Commission, are the cause of approximately 5% of all hospital admissions. Pharmacovigilance is the procedure and the science of monitoring the safety of medicinal products, including the collection and management of product safety information, the assessment of the information to identify any safety issues, the action to be taken and the assessment of the procedure which has been followed and the results which have been obtained. The Commission wishes to improve the current system of pharmacovigilance by simplifying procedures, increasing transparency and better defining the role and involvement of the parties concerned. I believe, however, that there is scope for further changes, particularly with regard to consumer protection and data protection: for example, consumers and health professionals should be able to have full access to the European Eudravigilance database in order to prevent the recurrence of adverse reactions to medicinal products, and they should be able to make use of not only the web format for announcements, but also other tools such as email, fax or telephone. Furthermore, in my opinion, funding for monitoring systems should continue to be public so that the responsibility of the authorities can be recognised."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph